In a report released yesterday, Paul Choi from Goldman Sachs maintained a Sell rating on FibroGen (FGEN – Research Report). The company’s shares closed yesterday at $2.16.
According to TipRanks, Choi is a 4-star analyst with an average return of 8.0% and a 55.68% success rate. Choi covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, FibroGen, and Ascendis Pharma.
The analyst consensus on FibroGen is currently a Moderate Sell rating.
The company has a one-year high of $20.90 and a one-year low of $0.33. Currently, FibroGen has an average volume of 2.64M.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen (FGEN) Company Description:
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Read More on FGEN:
- FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
- FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
- Unusually active option classes on open March 14th
- FibroGen appoints Deyaa Adib as CMO
- FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
